Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2000 Jan;13(1):144-66, table of contents.
doi: 10.1128/CMR.13.1.144.

Update on meningococcal disease with emphasis on pathogenesis and clinical management

Affiliations
Review

Update on meningococcal disease with emphasis on pathogenesis and clinical management

M van Deuren et al. Clin Microbiol Rev. 2000 Jan.

Abstract

The only natural reservoir of Neisseria meningitidis is the human nasopharyngeal mucosa. Depending on age, climate, country, socioeconomic status, and other factors, approximately 10% of the human population harbors meningococci in the nose. However, invasive disease is relatively rare, as it occurs only when the following conditions are fulfilled: (i) contact with a virulent strain, (ii) colonization by that strain, (iii) penetration of the bacterium through the mucosa, and (iv) survival and eventually outgrowth of the meningococcus in the bloodstream. When the meningococcus has reached the bloodstream and specific antibodies are absent, as is the case for young children or after introduction of a new strain in a population, the ultimate outgrowth depends on the efficacy of the innate immune response. Massive outgrowth leads within 12 h to fulminant meningococcal sepsis (FMS), characterized by high intravascular concentrations of endotoxin that set free high concentrations of proinflammatory mediators. These mediators belonging to the complement system, the contact system, the fibrinolytic system, and the cytokine system induce shock and diffuse intravascular coagulation. FMS can be fatal within 24 h, often before signs of meningitis have developed. In spite of the increasing possibilities for treatment in intensive care units, the mortality rate of FMS is still 30%. When the outgrowth of meningococci in the bloodstream is impeded, seeding of bacteria in the subarachnoidal compartment may lead to overt meningitis within 24 to 36 h. With appropriate antibiotics and good clinical surveillance, the mortality rate of this form of invasive disease is 1 to 2%. The overall mortality rate of meningococcal disease can only be reduced when patients without meningitis, i.e., those who may develop FMS, are recognized early. This means that the fundamental nature of the disease as a meningococcus septicemia deserves more attention.

PubMed Disclaimer

Figures

FIG. 1
FIG. 1
The time elapsed between the first symptoms of disease (noted by the patient, parents, or relatives) and the moment of hospital admission of 140 patients with invasive meningococcal disease admitted from 1984 to 1998 to the ICU of the University Hospital, Nijmegen. Patients are classified into four groups: (i) no shock and no meningitis (n = 13), (ii) shock and no meningitis (n = 57), (iii) shock and meningitis (n = 20), and (iv) meningitis without shock (n = 50). Shock is defined as the presence of systolic hypotension, refractory to a fluid bolus and requiring vasopressors, of <100 mm Hg in adults, <85 mm Hg in children 4 to 14 years old, and <75 mm Hg in children younger than 4 years. Meningitis is defined as >108 leukocytes/liter or CSF or, when no spinal tap is performed, the presence of nuchal rigidity (163, 475); J. F. Sinclair, C. H. Sheoch, and D. Hallworth, Letter, Lancet ii:38, 1987). Horizontal lines indicate median values. Crosses refer to fatalities.
FIG. 2
FIG. 2
Time of death for 24 patients who died of meningococcal septic shock, with respect to the time of hospital admission (continuous line) or ICU admission (dotted line).

References

    1. Abramson J S, Spika J S. Persistence of Neisseria meningitidis in the upper respiratory tract after intravenous antibiotic therapy for systemic meningococcal disease. J Infect Dis. 1985;151:370–371. - PubMed
    1. Achtman M. Global epidemiology of meningococcal disease. In: Cartwright K, editor. Meningococcal disease. Chichester, United Kingdom: John Wiley & Sons, Ltd.; 1995. pp. 159–175.
    1. Achtman M, Wall R A, Bopp M, Kusecek B, Morelli G, Saken E, Hassan King M. Variation in class 5 protein expression by serogroup A meningococci during a meningitis epidemic. J Infect Dis. 1991;164:375–382. - PubMed
    1. Aiuto L T, Barone S R, Cohen P S, Boxer R A. Recombinant tissue plasminogen activator restores perfusion in meningococcal purpura fulminans. Crit Care Med. 1997;25:1079–1082. - PubMed
    1. Algren J T, Lal S, Cutliff S A, Richman B J. Predictors of outcome in acute meningococcal infection in children. Crit Care Med. 1993;21:447–452. - PubMed

MeSH terms